|
Dr. Ryan Million is a Principal and founding member and manager of Trinity�s New York City office. Dr. Million�s practice at Trinity focuses on licensing and acquisition due diligence, revenue forecasting, marketing data analysis and business strategy for pharmaceutical companies in several therapeutic areas. In the area of oncology L&A, Dr. Million�s efforts have resulted in the successful licensing of two oncology drugs for one of Trinity�s core clients. In addition, Dr. Million brings experience from engeneOS, Inc., a venture-backed biotechnology start-up company in Waltham, MA, where he was a member of the business development team, delivering strategy, competitive intelligence and technology due diligence. Dr. Million completed his doctorate training in the Genetics Department at Harvard University publishing several peer-reviewed scientific papers on the ABL oncogene (target of Novartis�s Gleevec) and a mouse model of chronic myeloid leukemia. Dr. Million attended the University of California, San Diego where he earned a B.S. in Chemistry/Biochemistry, graduating cum laude and Phi Beta Kappa. | 